BCR-ABL kinase Inhibitors
1 drugsAbout BCR-ABL kinase
BCR-ABL kinase is an aberrant tyrosine kinase resulting from a chromosomal translocation, forming the Philadelphia chromosome. This abnormal kinase drives uncontrolled cell proliferation, particularly in certain blood cancers. It is a validated drug target implicated in a specific therapeutic area.
BCR-ABL's role in blood cancers makes it a crucial target for therapeutic intervention. Currently, there is no genetic evidence data available linking BCR-ABL directly to other diseases. Its clinical significance is underscored by the existence of FDA-approved drugs.
BCR-ABL kinase is targeted by one FDA-approved small molecule drug, BOSULIF. This drug is marketed by PF PRISM CV. Further research and novel inhibitors hold promise for improving treatment outcomes.
Top BCR-ABL kinase Drugs
The competitive landscape is highly concentrated, with only one company, PF PRISM CV, holding approvals.
High market concentration suggests high barriers to entry or potential for acquisition of PF PRISM CV.
BCR-ABL kinase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets BCR-ABL kinase, using small molecule modality.
The lack of diverse modalities indicates a whitespace opportunity for antibody or PROTAC-based BCR-ABL inhibitors.
BCR-ABL kinase Clinical Trials 34 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on BCR-ABL kinase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 11 | 3 | 1 | 79% |
| Phase 2 | 12 | 7 | 3 | 2 | 70% |
| Phase 3 | 5 | 3 | 0 | 2 | 100% |
| Phase 4 | 2 | 0 | 1 | 1 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
BCR-ABL kinase Drug Approval Timeline (2012 - 2012)
The first and only drug, BOSULIF, was approved in 2012.
The single approval in 2012 suggests a saturated market or challenges in developing novel BCR-ABL inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 16 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on BCR-ABL kinase. A trial counts if an approved drug acting on BCR-ABL kinase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.